

CollPlant Raises USD 2.2 Million in Private Placement Transaction

Option Provided for Up to an Additional USD 1 Million Investment by February 28, 2016

Yehiel Tal, CEO of CollPlant: "This successful round of funding is due to investors abroad having discovered the commercial potential of CollPlant."

Ness Ziona, November 23, 2015, CollPlant (TASE: CLPT), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products, today announced that it has signed a binding agreement for an investment of USD 2.2 million from two foreign investors, in a private placement transaction. In addition, the investors have been given the option for an additional investment of up to USD 1 million, exercisable until February 28, 2016.

Yehiel Tal, CEO of CollPlant: "This successful round of financing is a testament by investors to the commercial potential of CollPlant's technology and pipeline. Notably, we have made significant progress in recent months, reporting positive results for Vergenix™FG (Flowable Gel) and Vergenix™STR (Soft Tissue Repair Matrix). In parallel with our preparations to obtain CE Marking, we are working to create the infrastructure to commence sales in Europe. In addition, we are discussing possible joint ventures with leading players in the industry in order to accelerate the penetration of our products into markets abroad, including within Europe and the U.S."

Initial investment: Under terms of the agreement, the Company will issue a total of 15,512,000 ordinary shares at a price of NIS 0.55 per ordinary share, in return for USD 2.2 million. The investors will also receive a total of 7,756,000 options, which are exercisable for three years and can be converted into ordinary shares at a price of NIS 0.80 per option. The total number of shares in the initial investment post-issue represents 5.50% of the Company's issued and paid-up share capital (the shares and options together represent 5.32% fully diluted).

Additional investment: Under the agreement, the investors have been granted the option for an additional investment, which can be exercised from the date of signature until February 28, 2016, of up to USD 500,000 per investor (totaling up to USD 1 million), in return for ordinary shares at

a price per ordinary share that shall be the higher of: (1) the average of the five trading days that preceded the notice of exercise, or (2) the share price of the initial investment (namely NIS 0.55). If the investors decide not to exercise the option by the end of the additional investment period, it will expire and the investors will not have any right to said additional investment. In addition, subject to exercise of the option for additional investment, the investors will receive options for ordinary shares equal to 50% of the amount of ordinary shares purchased in the additional investment, with each option being exercisable for a period of three years from the date of said additional investment for an ordinary share at an exercise price of NIS 0.80.

About CollPlant

CollPlant is a clinical-stage regenerative medicine company leveraging its proprietary, plant-based rhCollagen technology for the development and commercialization of tissue repair products, initially for the orthobiologics and advanced wound care markets. The Company's cutting-edge technology is designed to generate and process proprietary recombinant human collagen (rhCollagen), among other patent-protected recombinant proteins. Given that CollPlant's rhCollagen is identical to the type I collagen produced by the human body, it offers significant advantages compared to currently marketed tissue-derived collagen, including improved biofunctionality, superior homogeneity and reduced risk of immune response. The Company's broad development pipeline includes biomaterials indicated for orthopedics and advanced wound healing. Lead products include: Vergenix™STR (Soft Tissue Repair Matrix), for the treatment of tendinopathy; Vergenix™FG (Flowable Gel) wound filler, for treatment of acute and chronic wounds, and; Vergenix™BVF (Bone Void Filler), for use in spinal fusion procedures and trauma. CollPlant's business strategy includes proprietary development and manufacturing of tissue repair products and their commercialization and distribution, together with leading third parties, alongside alliances with leading companies for joint development, manufacturing and marketing of additional products.

For more information about CollPlant, visit <http://www.collplant.com>

Contact at CollPlant:

Eran Rotem

Chief Financial Officer

Tel: +972-73-2325600/612

Email: Eran@collplant.com



Contact at Rx Communications Group, LLC:

Paula Schwartz (for US Investors)

Senior Vice President

Tel: +1-917-322-2216

Email: pschwartz@RxIR.com